TELMISARTAN tablet

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

TELMISARTAN (UNII: U5SYW473RQ) (TELMISARTAN - UNII:U5SYW473RQ)

から入手可能:

Amneal Pharmaceuticals of New York LLC

INN（国際名）:

TELMISARTAN

構図:

TELMISARTAN 20 mg

投与経路:

ORAL

処方タイプ:

PRESCRIPTION DRUG

適応症:

Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of

製品概要:

Telmisartan tablets USP, 20 mg, are supplied as white to off-white, round shaped uncoated tablets, debossed with ‘AN’ on one side and ‘291’ on the other side. They are available as follows: Bottles of 30:                                                  NDC 53746-291-30 Telmisartan tablets USP, 40 mg, are supplied as white to off-white, modified capsule shaped uncoated tablets, debossed with ‘AN’ on one side and ‘292’ on the other side. They are available as follows: Bottles of 30:                                                  NDC 53746-292-30 Telmisartan tablets USP, 80 mg, are supplied as white to off-white, modified capsule shaped uncoated tablets, debossed with ‘AN293’ on one side and plain on the other side. They are available as follows: Bottles of 30:                                                  NDC 53746-293-30 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Tablets should not be removed from bottles until immediately before administration.

認証ステータス:

Abbreviated New Drug Application

製品の特徴

TELMISARTAN- TELMISARTAN TABLET
AMNEAL PHARMACEUTICALS OF NEW YORK LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
TELMISARTAN TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
TELMISARTAN TABLETS.
TELMISARTAN TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1998
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
WHEN PREGNANCY IS DETECTED, DISCONTINUE TELMISARTAN AS SOON AS
POSSIBLE. (5.1, 8.1)
DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE
INJURY AND DEATH
TO THE DEVELOPING FETUS. (5.1, 8.1)
INDICATIONS AND USAGE
Telmisartan tablets are an angiotensin II receptor blocker (ARB)
indicated for:
Treatment of hypertension, to lower blood pressure. Lowering blood
pressure reduces the risk of fatal
and nonfatal cardiovascular events, primarily strokes and myocardial
infarctions. (1.1)
Cardiovascular (CV) risk reduction in patients unable to take ACE
inhibitors. (1.2)
DOSAGE AND ADMINISTRATION
May be administered with or without food. (2.1)
When used for cardiovascular risk reduction, monitoring of blood
pressure is recommended, and if
appropriate, adjustment of medications that lower blood pressure may
be necessary. (2.2) INDICATION STARTING DOSE DOSE RANGE
Hypertension (2.1)
40 mg once daily 40 mg to 80 mg once daily
Cardiovascular Risk Reduction (2.2) 80 mg once daily 80 mg once daily
DOSAGE FORMS AND STRENGTHS
Tablets: 20 mg, 40 mg, 80 mg (3)
CONTRAINDICATIONS
Known hypersensitivity (e.g., anaphylaxis or angioedema) to
telmisartan or any other component of this
product. (4)
Do not co-administer aliskiren with telmisartan in patients with
diabetes. (4)
WARNINGS AND PRECAUTIONS
Avoid fetal or neonatal exposure. (5.1)
Hypotension: Correct any volume or salt depletion before initiating
therapy. Observe for signs and
symptoms of hypotension. (5.2)
Monitor carefully in patients with impaired hepatic (5.4) or renal
function. (5.5)
Avoid concomitant use of an ACE inhibitor and angiote